NVIDIA investment boost for CHARM Therapeutics
NVentures, the venture investment arm of US tech giant NVIDIA, has injected an undisclosed sum into CHARM Therapeutics – a 3D deep learning biotech company which recently announced it was moving its drug discovery team from London to the Kadans’ facility at Babraham Research Campus.
The investment represents a major milestone for CHARM, enabling the company to further deliver on its research and development activities in the area of novel medicines for oncology.
CHARM is at the forefront of deep learning-enabled drug discovery research, utilising advanced computing and machine learning to develop novel small molecule therapeutics for cancers that have long been considered difficult to drug.
The company’s unique approach focuses on leveraging the power of machine learning algorithms to identify novel molecules through protein-ligand co-folding, thus accelerating the development of new treatments. The investment enables CHARM to continue to fund its rapidly growing organisation while harnessing the power of NVIDIA’s accelerated computing platform.
CHARM, which has its HQ in London, has raised $70 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology.
It is supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and grep -vc.
“We are thrilled to be collaborating with NVIDIA as they share our vision for the future of drug discovery,” said Laksh Aithani, CEO and co-founder of CHARM. “With this investment and continued use of NVIDIA’s advanced computing technology, we believe we can accelerate the development of our small molecule therapies, bringing them to patients faster and more efficiently than ever before.”
Mohamed “Sid” Siddeek, head of NVentures, NVIDIA added: “Investing in CHARM allows us to further support the application of AI and machine learning to drug discovery, demonstrating how accelerated computing can change the face of modern medicine.”
